Venture-Backed Startups

BioAmp Diagnostics develops a chemistry-based rapid diagnostic pipeline (DETECT: Dual-Enzyme Trigger-Enabled Cascade Technology) that delivers infection results in minutes to guide antibiotic prescribing, initially targeting complicated urinary tract infections. The technology is intended to help physicians select the correct antibiotic and support efforts to combat antibiotic resistance.

1 investor

Bioarchitech develops multifunctional cancer immunotherapies derived from viral genetic code, including an intravenous engineered Vaccinia virus therapy (BA-V151) for metastatic cancer and a self-amplifying RNA intratumoural therapy (BA-R166) for early-stage cancers. Its candidates aim to both kill tumour cells and induce anti-tumour immunity, with initial focus on oesophageal and lung cancer.

1 investor

0 investors

BioAscent provides integrated drug discovery services, including assay development, target analysis, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry, and compound management with in-house diversity and fragment libraries. It serves pharmaceutical and biotech clients from its site in Newhouse, Scotland.

1 investor

0 investors

BioAtlantis develops natural compounds extracted from renewable marine and terrestrial resources to reduce stress in crops, animals, and humans by strengthening natural defence systems. The company participates in EU Horizon Europe-funded research projects in agricultural and biological science.

1 investor

Biobase provides a data infrastructure layer that normalizes, unifies, and indexes clinical data from disparate systems (EHRs, LIMS, HL7, FHIR, VCF, genomics) into one queryable, research-ready network. It connects healthcare institutions and life sciences/biopharma companies, letting users request patient cohorts in plain language while data stays in institutional custody with HIPAA-aligned de-identification and audit trails.

1 investor

0 investors

BioBlends develops biopreservation products that use volatile organic compounds from beneficial bacteria, combined with bioinformatics and experimental validation, to control preservative-resistant microorganisms and fungal contamination in food. Its solutions extend shelf life across food matrices without chemical residues, serving industrial food producers such as baked goods manufacturers.

1 investor

BioBond is a materials technology company developing plant-based, low-VOC adhesives and protective coatings for industries including packaging, construction, automotive, textiles, furniture, marine, and aerospace. Its products, such as the BioCoat SUP250 polyurethane coating, are made in the USA without added microplastics and target healthcare, commercial, industrial, and food-safe environments.

1 investor

Biobot pioneers wastewater epidemiology, monitoring pathogens and substances in sewage to provide real-time public health surveillance at the community level. The company serves public health agencies, vaccine manufacturers, and hospital systems globally.

9 investors

0 investors

0 investors

BioBTX develops ICCP technology that converts end-of-life plastic waste and biomass into renewable aromatics (benzene, toluene, and xylenes) for use as drop-in chemical building blocks in the chemical industry. Based in the Netherlands, it is building PETRA, a commercial-scale plant in Delfzijl, and licenses its technology for circular aromatics production.

2 investors

BioCam designs and manufactures a pill-sized endoscopic capsule for imaging the gastrointestinal tract, paired with AI software for automatic real-time detection of abnormalities. The system includes a telemedicine platform and a patient mobile app, aimed at non-invasive at-home GI diagnosis with remote physician monitoring.

1 investor

1 investor

0 investors

0 investors

0 investors

Biocare Medical develops automated staining instruments and reagents, including over 300 optimized antibodies and in-house detection technologies, as an integrated platform for immunohistochemistry (IHC), in situ hybridization (ISH), and FISH workflows. Its products serve pathology and diagnostic laboratories.

1 investor

Biocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.

1 investor

Biocartis develops Idylla, a fully automated real-time PCR molecular testing system that delivers biomarker results in about three hours for oncology applications. The company targets clinical labs, oncologists, and pathologists, and runs partnership programs with pharmaceutical and diagnostic companies.

4 investors

BioCatch develops behavioral biometric authentication technology for fraud detection and identity verification.

8 investors

0 investors